<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPathology</journal-id><journal-title-group><journal-title>Open Journal of Pathology</journal-title></journal-title-group><issn pub-type="epub">2164-6775</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojpathology.2018.81002</article-id><article-id pub-id-type="publisher-id">OJPathology-81540</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  A Review on Survivin as a Prognostic and Therapeutic Cancer Biomarker
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amal</surname><given-names>Ahmed Ismail</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Unaizah College of Pharmacy, Qassim University, Unaizah, KSA</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>amal.zumrawy2012@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>11</month><year>2017</year></pub-date><volume>08</volume><issue>01</issue><fpage>15</fpage><lpage>23</lpage><history><date date-type="received"><day>4,</day>	<month>December</month>	<year>2017</year></date><date date-type="rev-recd"><day>26,</day>	<month>December</month>	<year>2017</year>	</date><date date-type="accepted"><day>29,</day>	<month>December</month>	<year>2017</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Survivin is an antiapoptotic protein expressed in tumor cells that correlates with aggressiveness, prognosis and treatment. Objective: This review summarizes significance of survivin expression among different tumor types highlighting the potential value of survivin as an important biomarker that may have an impact on patient’s response to therapy with prognostic implications.
 
</p></abstract><kwd-group><kwd>Survivin</kwd><kwd> Prognostic Biomarker</kwd><kwd> Cancer</kwd><kwd> Antiapoptotic</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The antiapoptotic survivin is a 16.5 kD wild-type protein consisting of 142 amino acids in length encoded by the BIRC5 gene at chromosome 17 [<xref ref-type="bibr" rid="scirp.81540-ref1">1</xref>] and it is expressed in fetal tissue and tumor cells [<xref ref-type="bibr" rid="scirp.81540-ref2">2</xref>] . The caspases (cysteine-aspartic proteases) are intracellular cysteine protease enzymes (such as caspase-3 and -7) that are involved in the regulation of programmed cell death (apoptosis) to maintain cellular homeostasis during development. Caspases are activated by initiator caspases, like caspase-9. Their activation will sequentially activate other executioner caspases which in turn result in enhanced cellular degradation and apoptotic morphological changes [<xref ref-type="bibr" rid="scirp.81540-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref4">4</xref>] . Deregulation and inhibition of apoptosis is a known mechanism of cancerization and cancer progression. As survivin mainly functions as an anti-apoptotic protein, its expression in tumor cells was found to be correlated with aggressiveness and adverse clinical prognosis making it a promising biomarker or an indicator of tumor aggressiveness and/or response to therapy [<xref ref-type="bibr" rid="scirp.81540-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref6">6</xref>] .</p><p>Survivin down regulates p53 [<xref ref-type="bibr" rid="scirp.81540-ref7">7</xref>] . Overexpression of survivin may overcome checkpoints of the cell cycle and result in increased mitosis and lead to the transformation to malignant cells [<xref ref-type="bibr" rid="scirp.81540-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref10">10</xref>] .</p></sec><sec id="s2"><title>2. Survivin and Bladder Cancer</title><p>studies relate survivin to survivin overexpression is strongly predictive of recurrence, progression specially mortality in bladder cancer and the malignant progression of urothelial carcinoma of the urinary bladder [<xref ref-type="bibr" rid="scirp.81540-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref12">12</xref>] . Other studies showed that number of positive tumor cells increasing with the grade of the tumor [<xref ref-type="bibr" rid="scirp.81540-ref13">13</xref>] . other studies detect urine survivin sensitivity in comparison with the cystoscopy as a standard method but results showed less than 80% sensitivity [<xref ref-type="bibr" rid="scirp.81540-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref15">15</xref>] .</p></sec><sec id="s3"><title>3. Survivinin Breast Cancer</title><p>Positive expression of survivin in breast cancer predicted a significantly higher risk of disease recurrence and is shown to be associated with lymph node metastasis (P value = 0.01) [<xref ref-type="bibr" rid="scirp.81540-ref16">16</xref>] . The rate of survivin expression seems to correlate with the sensitivity of survivin detection methods. In one study using survivin immunohistochemistry, survivin was expressed in 65.3% (55.2% - 90.0%) of breast cancer samples while survivin mRNA detection using RT-PCR was identified in 93.6% (90% - 97%) of cases. The same study showed association of survivin expression with HER2 overexpression, vascular endothelial growth factor (VEGF) and, urokinase plasminogen activator (uPA)/PAI-1 [<xref ref-type="bibr" rid="scirp.81540-ref17">17</xref>] .</p><p>A study from Egypt investigated the expression of survivin in correlation with the clinicopathological parameters, proliferation and molecular classification of breast carcinoma. In that study, survivin expression (detected in 78.5% of breast carcinomas) was related to tumor size, high histologic grade, lymph node metastases, advanced tumor stage, MIB-1 index and negative estrogen/progesterone receptor status. Notably, the subcellular localization of survivin significantly related to histologic grade, stage and lymph node involvement [<xref ref-type="bibr" rid="scirp.81540-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref19">19</xref>] . In another study on 420 non-metastatic breast cancer tissue samples using the ELISA method, a high survivin expression was detected in 90% of cases and indicated a significantly poor prognosis on long term follow up [<xref ref-type="bibr" rid="scirp.81540-ref19">19</xref>] .</p></sec><sec id="s4"><title>4. Survivin Expression in Head and Neck Cancer</title><p>Different types of head and neck neoplasms have been studied for survivin expression in different studies. Expression of survivin and COX2 was related to the ability of invasion and cancerization in ameloblastoma [<xref ref-type="bibr" rid="scirp.81540-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref21">21</xref>] . Overexpression of these 2 markers in oral mucosal premalignant lesions suggests a role in early stages of oral carcinogenesis [<xref ref-type="bibr" rid="scirp.81540-ref22">22</xref>] . Another study handled localization and prognostic value of nuclear and cytoplasmic survivin expression in the pre-therapeutic biopsies of 71 oral and oropharyngeal squamous cell carcinoma (OSCC) patients. Their results indicated that nuclear versus cytoplasmic survivin correlated with prognostic outcome. Cytoplasmic localization of survivin is also considered a potential therapeutic strategy [<xref ref-type="bibr" rid="scirp.81540-ref23">23</xref>] . Cases of oral SCC together with distant metastatic lesions were analyzed for expression of survivin by immunohistochemistry and Western blotting. Out of the 91 cases (82.7%) of primary SCC and all metastases (seven cases, 100%) were positive for survivin expression, there was no significant correlation between survivin expression and age, sex, tumor size, and the presence of lymph node and distant metastases. Survivin expression was higher in less differentiated tumors and was prognostically significant (P &lt; 0.05) [<xref ref-type="bibr" rid="scirp.81540-ref24">24</xref>] .</p><p>Correlation between survivin mRNA expression and clinicopathologic features or prognosis of OSCC patients was analyzed. Small interfering RNA technology was used to detect and decrease cancerous cells expression of survivin and detect the effect on its sensitivity to chemotherapeutic drugs [<xref ref-type="bibr" rid="scirp.81540-ref25">25</xref>] .</p></sec><sec id="s5"><title>5. Survivin and Digestive Tract Tumors</title><p>The role of survivin in colonic tissue transformation of dysplasia low dysplasia to high dysplasia with P53 and B catenin was studied and results showed that positivity of survivin is raised by six to twelve folds in tumor cells [<xref ref-type="bibr" rid="scirp.81540-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref27">27</xref>] .</p><p>Regarding prognosis of recurrent colorectal carcinoma surviving considered as patients with negative survivin tumors had a five-year survival rate of 94.4% compared with 44.8% for patients with Survivin positive tumors [<xref ref-type="bibr" rid="scirp.81540-ref28">28</xref>] .</p><p>(New Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant gastro was studied and concluded that the use of AAV-mediated survivin mutant (Cys84Ala) is a promising strategy in colon cancer gene therapy) [<xref ref-type="bibr" rid="scirp.81540-ref29">29</xref>] .</p><p>Other Studies aimed downregulation of survivin by induction of EPR-1 cDNA noticed a decrease in tumor growth and increased response to anticancer agents used for treatment of colon cancer [<xref ref-type="bibr" rid="scirp.81540-ref30">30</xref>] . Finally, the overall survival rate is decreased in those studied for showed positive survivin [<xref ref-type="bibr" rid="scirp.81540-ref31">31</xref>] .</p></sec><sec id="s6"><title>6. Survivin and Genital Tract Tumors</title><p>No survivin mRNA was expressed in all normal ovarian specimens, while it appeared in 73% of ovarian carcinomas, 47% of borderline ovarian carcinomas and 19% of benign ovarian tumors study suggest that survivin is associated with progression of ovarian carcinoma [<xref ref-type="bibr" rid="scirp.81540-ref32">32</xref>] .</p><p>A retrospective review on Survivin status affects prognosis and chemosensitivity in epithelial ovarian was done on 90 patients with a median follow-up time of 51 months. The reverse transcription-polymerase chain reaction and flow cytometry were applied to detect survivin expression levels and cell apoptotic percentages. Results showed that cytoplasmic survivin protein expression is an independent molecular marker for prognosis. Sequence-specific shRNA targeting survivin can effectively suppress survivin expression, enhance apoptosis, and increase the sensitivity of ovarian cancer cells to paclitaxel but not to cisplatin [<xref ref-type="bibr" rid="scirp.81540-ref33">33</xref>] .</p><p>Studies on endometrial carcinoma associated with PTEN abnormalities found that PTEN may interfere with the process of apoptosis and by promoting survivin expression [<xref ref-type="bibr" rid="scirp.81540-ref34">34</xref>] . Data indicate that a survivin-specific immune response may be induced spontaneously in patients, further fortifying the eligibility of survivin as an immunotherapeutic target [<xref ref-type="bibr" rid="scirp.81540-ref35">35</xref>] .</p></sec><sec id="s7"><title>7. Survivin Expression in Lymph Nodes</title><p>survivin over expression might be a poor prognostic factor for patients with NHL. However, more large-scale studies are needed to confirm these findings [<xref ref-type="bibr" rid="scirp.81540-ref36">36</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref37">37</xref>] . Survivin suggested as an attractive target for new anti-cancer intervention of NHL and vector-based survivin-shRNA could clearly reduce the expression of survivin and induce cell apoptosis and growth inhibition of malignant cells [<xref ref-type="bibr" rid="scirp.81540-ref36">36</xref>] .</p></sec><sec id="s8"><title>8. Survivin and Renal Cell Carcinoma</title><p>Survivin was suggested as a prognostic marker in renal cell carcinoma. Expression was correlated with prognosis and clinicopathological features, and it could be used in the future as a biomarker for in therapy after more comprehensive studies [<xref ref-type="bibr" rid="scirp.81540-ref38">38</xref>] .</p></sec><sec id="s9"><title>9. Survivin and Hepatocellular Carcinoma</title><p>Survivin expression correlates with nuclear and histologic grade, microvascular invasion, increased mitotic figures, local recurrence, and poor prognosis. RT-PCR detection test for survivin along with immunohistochemistry of 20 cases of hepatocellular carcinoma and one case diagnosed as intrahepatic cholangiocarcinoma. Low levels of Survivin mRNA can be detected in normal and liver tissue [<xref ref-type="bibr" rid="scirp.81540-ref39">39</xref>] . Overexpression of the protein is associated with positive nuclear p53 nuclear staining [<xref ref-type="bibr" rid="scirp.81540-ref40">40</xref>] . The concentration of the protein may reflect the prognosis of the case but this is still needs more studies [<xref ref-type="bibr" rid="scirp.81540-ref41">41</xref>] . Two survivin scoring methods―topoisomerase II α nuclear labelling index (LI) and tumor differentiation―were analyzed by researchers for specificity results showed that Survivin nuclear LI correlated significantly with tumor cell proliferation [<xref ref-type="bibr" rid="scirp.81540-ref42">42</xref>] .</p></sec><sec id="s10"><title>10. Survivin in Pancreatic Cancer</title><p>A study correlated survivin mRNA, promoter’s expression and radio sensitivity of the tumors showing a very promising result regarding radio-sensitivity and survivin inhibitors treatment usage and improvement of prognosis [<xref ref-type="bibr" rid="scirp.81540-ref43">43</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref44">44</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref45">45</xref>] [<xref ref-type="bibr" rid="scirp.81540-ref46">46</xref>] .</p><p>Targeting survivin as an upstream regulator of mitochondrial dependent apoptosis, not only enhance apoptosis but also suppress angiogenesis [<xref ref-type="bibr" rid="scirp.81540-ref47">47</xref>] .</p></sec><sec id="s11"><title>11. Survivin in Head and Neck Tumors</title><p>Survivin expression in head and neck squamous cell carcinoma (HNSCC) as assessed by immunohistochemical staining and western blot and then compared with normal tissue was significantly associated with loss of differentiation in tumors and in that study, Bcl-XL was associated with nodal metastasis (P &lt; 0.001) [<xref ref-type="bibr" rid="scirp.81540-ref48">48</xref>] .</p><p>Furthermore, Oxaliplatin treatment for HNSCC was studied in radioresistant cases with high survivin levels and found to be effective in reducing the resistant to radiation therapy [<xref ref-type="bibr" rid="scirp.81540-ref49">49</xref>] .</p></sec><sec id="s12"><title>12. Conclusion</title><p>Survivin is an important biomarker in diverse types of malignant neoplasms originating in different organs. Correlation of survivin expression with adverse tumor characteristics and less favorable patient’s outcome indicates the importance of including survivin in the biomarker panel used to evaluate malignancies with therapeutic and prognostic implications.</p></sec><sec id="s13"><title>Acknowledgements</title><p>I am grateful to Prof Abbas Agaimy for assistance in improving the manuscript significantly.</p></sec><sec id="s14"><title>Cite this paper</title><p>Ismail, A.A. (2018) A Review on Survivin as a Prognostic and Therapeutic Cancer Biomarker. Open Journal of Pathology, 8, 15-23. https://doi.org/10.4236/ojpathology.2018.81002</p></sec><sec id="s15"><title>Abbreviations</title><p>BIRC5: Baculoviral inhibitor of apoptosis repeat-containing 5</p><p>HER2: Human epidermal growth factor receptor 2</p><p>VEGF: Vascular endothelial growth factor</p><p>PAI-1: Plasminogen activator inhibitor-1</p><p>MIB-1: Mindbomb E3 ubiquitin protein ligase 1</p><p>COX2: Cyclooxygenase 2</p><p>OSCC: Oral Squamous Cell Carcinoma</p><p>SCC: Squamous Cell Carcinoma</p><p>AAV: Adeno-associated virus</p><p>EPR-1 cDNA: Effector cell protease receptor 1 complementary DNA</p><p>PTEN: Phosphatase and tensin homolog</p><p>NHL: Non-Hodgkin lymphoma</p><p>Bcl-2: B cell lymphoma 2</p><p>Bcl-XL: B cell lymphoma extra large</p></sec></body><back><ref-list><title>References</title><ref id="scirp.81540-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Altieri, D.C. (1994) Splicing of Effector Cell Protease Receptor-1 mRNA Is Modulated by an Unusual Retained Intron. Biochemistry, 33, 13848-13855.  
https://doi.org/10.1021/bi00250a039</mixed-citation></ref><ref id="scirp.81540-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, C., Lohmann, C.M., Cotsonis, G., Lawson, D. and Santoianni, R. (2003) (ASCP) Survivin Expression in Ovarian Carcinoma: Correlation with Apoptotic Markers and Prognosis. Modern Pathology, 16, 574-583.  
https://doi.org/10.1097/01.MP.0000073868.31297.B0</mixed-citation></ref><ref id="scirp.81540-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wheatley, S.P. and McNeish, I.A. (2005) Survivin: A Protein with Dual Roles in Mitosis and Apoptosis. International Review of Cytology, 247, 35-88.  
https://doi.org/10.1016/S0074-7696(05)47002-3</mixed-citation></ref><ref id="scirp.81540-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Thornberry, N.A. and Lazebnik, Y. (1998) Caspases: Enemies within. Science, 281, 1312-1316. https://doi.org/10.1126/science.281.5381.1312</mixed-citation></ref><ref id="scirp.81540-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sollberger, G., Strittmatter, G.E., Garstkiewicz, M., Sand, J. and Beer, H.-D. (2014) Caspase-1: The Inflammasome and Beyond. Innate Immunity, 20, 115-125.  
https://doi.org/10.1177/1753425913484374</mixed-citation></ref><ref id="scirp.81540-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Altieri, D.C. (2003) Survivin, Versatile Modulation of Cell Division and Apoptosis in Cancer. Oncogene, 22, 8581-8589. https://doi.org/10.1038/sj.onc.1207113</mixed-citation></ref><ref id="scirp.81540-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z., Fukuda, S. and Pelus, L.M. (2004) Survivin Regulates the p53 Tumor Suppressor Gene Family. Oncogene, 23, 8146-8153.  
https://doi.org/10.1038/sj.onc.1207992</mixed-citation></ref><ref id="scirp.81540-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sah, N.K., Khan, Z., Khan, G.J. and Bisen, P.S. (2006) Structural, Functional and Therapeutic Biology of Survivin. Cancer Letters, 244, 164-171.  
https://doi.org/10.1016/j.canlet.2006.03.007</mixed-citation></ref><ref id="scirp.81540-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Fortugno, P., Wall, N.R., Giodini, A., O’Connor, D.S., Plescia, J., et al. (2002) Survivin Exists in Immunochemically Distinct Subcellular Pools and Is Involved in Spindle Microtubule Function. Journal of Cell Science, 115, 575-585.</mixed-citation></ref><ref id="scirp.81540-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Li, F. and Ling, X. (2006) Survivin Study: An Update of “What Is the Next Wave”? Journal of Cellular Physiology, 208, 476-486. https://doi.org/10.1002/jcp.20634</mixed-citation></ref><ref id="scirp.81540-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yin, W., Chen, N., Zhang, Y., et al. (2006) Survivin Nuclear Labeling Index: A Superior Biomarker in Superficial Urothelial Carcinoma of Human Urinary Bladder. Modern Pathology, 19, 1487-1497. https://doi.org/10.1038/modpathol.3800675</mixed-citation></ref><ref id="scirp.81540-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yildirim, U., Erdem, H., Kayikci, A., Sahin, A.F., Uzunlar, A.K. and Albayrak, A. (2010) Cyclooxygenase-2 and Survivin in Superficial Urothelial Carcinoma of the Bladder and Correlation with Intratumoural Microvessel Density. Journal of International Medical Research, 38, 1689-1699.  
https://doi.org/10.1177/147323001003800514</mixed-citation></ref><ref id="scirp.81540-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Margulis, V., Lotan, Y. and Shariat, S. (2008) Survivin: A Promising Biomarker for Detection and Prognosis of Bladder Cancer. World Journal of Urology, 26, 59-65.  
https://doi.org/10.1007/s00345-007-0219-y</mixed-citation></ref><ref id="scirp.81540-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Jeon, C., Kim, M., Kwak, C., Kim, H.H. and Ku, J.H. (2013) Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis. PLoS One, 8, e76719.  
https://doi.org/10.1371/journal.pone.0076719</mixed-citation></ref><ref id="scirp.81540-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Vriesema, J.L., Poucki, M.H., Kiemeney, L.A. and Witjes, J.A. (2000) Patient Opinion of Urinary Tests versus Flexible Urethra Cystoscopy in Follow-Up Examination for Superficial Bladder Cancer: A Utility Analysis. Urology, 56, 793-797.  
https://doi.org/10.1016/S0090-4295(00)00777-9</mixed-citation></ref><ref id="scirp.81540-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Ma, X., Wu, X., Liu, X. and Liu, L. (2014) Prognostic Significance of Survivin in Breast Cancer: Meta-Analysis. The Breast Journal, 20, 514-524.  
https://doi.org/10.1111/tbj.12303</mixed-citation></ref><ref id="scirp.81540-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Jha, K., Shukla, M. and Pandey, M. (2012) Survivin Expression and Targeting in Breast Cancer. Surgical Oncology, 21, 125-131.  
https://doi.org/10.1016/j.suronc.2011.01.001</mixed-citation></ref><ref id="scirp.81540-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Youssef, N.S., Hewedi, I.H. and Abd Raboh, N.M. (2008) Immunohistochemical Expression of Survivin in Breast Carcinoma: Relationship with Clinicopathological Parameters, Proliferation and Molecular Classification. Journal of the Egyptian National Cancer Institute, 20, 348-357.</mixed-citation></ref><ref id="scirp.81540-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J. and Duffy, M.J. (2006) Survivin Expression in Breast Cancer Predicts Clinical Outcome and Is Associated with HER2, VEGF, Urokinase Plasminogen Activator and PAI-1. Annals of Oncology, 17, 597-604.  
https://doi.org/10.1093/annonc/mdj121</mixed-citation></ref><ref id="scirp.81540-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Li, L., Zhang, X.L., Wang, P. and Liu, Y. (2014) Expression of Survivin in Ameloblastoma and Its Clinical Significance. Shanghai Journal of Stomatology, 23, 481-484.</mixed-citation></ref><ref id="scirp.81540-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Khan, Z., Tiwari, R.P., Mulherkar, R., Sah, N.K., Prasad, G., Shrivastava, B.R. and Bisen, P.S. (2009) Detection of Survivin and p53 in Human Oral Cancer: Correlation with Clinicopathologic Findings. Head Neck, 31, 1039-1048.</mixed-citation></ref><ref id="scirp.81540-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Uzawa, T.C.K., Shibahara, T., Yokoe, H., Noma, H. and Tanzawa, H. (2003) Expression of an Inhibitor of Apoptosis, Survivin, in Oral Carcinogenesis. Journal of Dental Research, 82, 607-611. https://doi.org/10.1177/154405910308200807</mixed-citation></ref><ref id="scirp.81540-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Engels, K., Knauer, S.K., Metzler, D., Simf, C., Struschka, O., Bier, C., Mann, W., Kovács, A.F. and Stauber, R.H. (2007) Dynamic Intracellular Survivin in Oral Squamous Cell Carcinoma: Underlying Molecular Mechanism and Potential as an Early Prognostic Marker. The Journal of Pathology, 211, 532-540.</mixed-citation></ref><ref id="scirp.81540-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Lo Muzio, L., Pannone, G., Staibano, S., Mignogna, M.D., Rubini, C., Mariggiò, M.A., Procaccini, M., Ferrari, F., De Rosa, G. and Altieri, D.C. (2003) Survivin Expression in Oral Squamous Cell Carcinoma. British Journal of Cancer, 89, 2244-2248.</mixed-citation></ref><ref id="scirp.81540-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Su, L., Wang, Y., Xiao, M., Lin, Y. and Yu, L. (2010) Up-Regulation of Survivin in Oral Squamous Cell Carcinoma Correlates with Poor Prognosis and Chemoresistance. Oral and Maxillofacial Pathology, 110, 484-491.</mixed-citation></ref><ref id="scirp.81540-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Kawasaki, H., Toyoda, M., Okuda, H.S.J., Watanabe, I., et al. (2001) Expression of Survivin Correlates with Apoptosis, Proliferation, and Angiogenesis during Human Colorectal Tumorigenesis. American Cancer Society, 91, 2026-2032.</mixed-citation></ref><ref id="scirp.81540-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Kim, P.J., Plescia, J., Clevers, H., Fearon, E.R. and Altieri, D.C. (2003) Survivin and Molecular Pathogenesis of Colorectal Cancer. The Lancet, 362, 205-209.</mixed-citation></ref><ref id="scirp.81540-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Sarelaa, A.I., Macadama, R.C., Farmerya, S.M., Markhamb, A.F. and Guilloua, P.J. (2000) Expression of the Antiapoptosis Gene, Survivin, Predicts Death from Recurrent Colorectal Carcinoma. Gut, 46, 645-650. https://doi.org/10.1136/gut.46.5.645</mixed-citation></ref><ref id="scirp.81540-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Tu, S.P., Cui, J.T., Liston, P., et al. (2004) Gene Therapy for Colon Cancer by Adeno-Associated Viral Vector-Mediated Transfer of Survivin Cys84Ala Mutant. Gastroenterology, 128, 361-375.</mixed-citation></ref><ref id="scirp.81540-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Yamamotoa, T., Manomeb, Y., Nakamuraa, M. and Tanigawaa, N. (2002) Downregulation of Survivin Expression by Induction of the Effector Cell Protease Receptor-1 Reduces Tumor Growth Potential and Results in an Increased Sensitivity to Anticancer Agents in Human Colon Cancer. European Journal of Cancer, 38, 2316-2324.</mixed-citation></ref><ref id="scirp.81540-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Kawasaki, H., Altieri, D.C., Lu, C.-D., Toyoda, M., Tenjo, T. and Tanigawa, N. (1998) Inhibition of Apoptosis by Survivin Predicts Shorter Survival Rates in Colorectal Cancer. Cancer Research, 58, 5071-5074.</mixed-citation></ref><ref id="scirp.81540-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Liguang, Z., Peishu, L., Hongluan, M., Hong, J., Rong, W., Wachtel, M.S. and Frezza, E.E. (2007) Survivin Expression in Ovarian Cancer. Experimental Oncology, 29, 121-125.</mixed-citation></ref><ref id="scirp.81540-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Chen, L., Liang, L., Yan, X., Liu, N., Gong, L., Pan, S., Lin, F., Zhang, Q., Zhao, H. and Zheng, F. (2013) Survivin Status Affects Prognosis and Chemosensitivity in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 23, 256-263.  
https://doi.org/10.1097/IGC.0b013e31827ad2b8</mixed-citation></ref><ref id="scirp.81540-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Pallares, J., Martínez-Guitarte, J.L., Dolcet, X., Llobet, D., Rue, M., Palacios, J., Prat, J. and Matias-Guiu, X. (2005) Survivin Expression in Endometrial Carcinoma: A Tissue Microarray Study with Correlation with PTEN and STAT-3. International Journal of Gynecological Pathology, 24, 247-253</mixed-citation></ref><ref id="scirp.81540-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Vanderstraeten, A., Everaert, T., Van Bree, R., et al. (2015) In Vitro Validation of Survivin as Target Tumor-Associated Antigen for Immunotherapy in Uterine Cancer. Journal of Immunotherapy, 38, 239-249.</mixed-citation></ref><ref id="scirp.81540-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Congmin, G., Mu, Z., Yihui, M. and Hanliang, L. (2006) Survivin—An Attractive Target for RNAi in Non-Hodgkin’s Lymphoma, Daudi Cell Line as a Model. Leukemia &amp; Lymphoma, 47, 1941-1948. https://doi.org/10.1080/10428190600725354</mixed-citation></ref><ref id="scirp.81540-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">He, C., Liu, Z., Ji, J. and Zhu, H. (2015) Prognostic Value of Survivin in Patients with Non-Hodgkin’s Lymphoma: A Meta-Analysis. International Journal of Clinical and Experimental Medicine, 8, 5847-5854.</mixed-citation></ref><ref id="scirp.81540-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Xie, Y., Ma, X., Gu, L., Li, H., Chen, L., et al. (2016) Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Scientific Reports, 6, Article No. 29794.</mixed-citation></ref><ref id="scirp.81540-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Fields, A.C., Cotsonis, G., Sexton, D., Santoianni, R. and Cohen, C. (2004) Survivin Expression in Hepatocellular Carcinoma: Correlation with Proliferation, Prognostic Parameters, and Outcome. Modern Pathology, 17, 1378-1385.  
https://doi.org/10.1038/modpathol.3800203</mixed-citation></ref><ref id="scirp.81540-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Kannangai, R., Wang, J., Liu, Q.Z., Sahin, F. and Torbenson, M. (2005) Survivin Overexpression in Hepatocellular Carcinoma Is Associated with p53 Dysregulation. International Journal of Gastrointestinal Cancer, 35, 53-60.  
https://doi.org/10.1385/IJGC:35:1:053</mixed-citation></ref><ref id="scirp.81540-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Montorsi, M., Maggioni, M., Falleni, M., Pellegrini, C., Donadon, M., Torzilli, G., Santambrogio, R., Spinelli, A., Coggi, G. and Bosari, S.H. (2007) Survivin Gene Expression in Chronic Liver Disease and Hepatocellular Carcinoma. Hepatogastroenterology, 54, 2040-2044.</mixed-citation></ref><ref id="scirp.81540-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Hasby, E.A. and Mokhtar, M.A. (2010) Survivin Immunohistochemical Expression in Hepatocellular Carcinoma: Correlation with Tumor Differentiation and Proliferation. Arab Journal of Gastroenterology, 11, 141-148.</mixed-citation></ref><ref id="scirp.81540-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Kami, K., Doi, R., Koizumi, M., Toyoda, E., Mori, T., Ito, D., Fujimoto, K., Wada, M., Miyatake, S. and Imamura, M. (2004) Survivin Expression Is a Prognostic Marker in Pancreatic Cancer Patients. Surgery, 136, 443-448.  
https://doi.org/10.1016/j.surg.2004.05.023</mixed-citation></ref><ref id="scirp.81540-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Waligórska-Stachura, J., Jankowska, A., Wasko, R., Liebert, W., et al. (2012) Survivin Prognostic Tumor Biomarker in Human Neoplasms—Review. Ginekologia Polska, 83, 537-540.</mixed-citation></ref><ref id="scirp.81540-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">R&amp;ouml;del, F., Sprenger, T., Kaina, B., Liersch, T., R&amp;ouml;del, C., Fulda, S. and Hehlgans, S. (2012) Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy. Current Medicinal Chemistry, 19, 3679-3688.</mixed-citation></ref><ref id="scirp.81540-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">R&amp;ouml;del, F., Reichert, S., Sprenger, T., Gaipl, U.S., Mirsch, J., Liersch, T., Fulda, S. and R&amp;ouml;del, C. (2011) The Role of Survivin for Radiation Oncology: Moving beyond Apoptosis Inhibition. Current Medicinal Chemistry, 18, 191-199.  
https://doi.org/10.2174/092986711794088362</mixed-citation></ref><ref id="scirp.81540-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Blanc-Brude, O.P., Mesri, M., Wall, N.R., et al. (2003) Therapeutic Targeting of the Survivin Pathway in Cancer: Initiation of Mitochondrial Apoptosis and Suppression of Tumor-Associated Angiogenesis. Clinical Cancer Research, 9, 2683-2692.</mixed-citation></ref><ref id="scirp.81540-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Sharma, H., Sen, S., Mathur, M., Bahadur, S. and Singh, N. (2004) Combined Evaluation of Expression of Telomerase, Survivin, and Anti-Apoptotic bcl-2 Family Members in Relation to Loss of Differentiation and Apoptosis in Human Head and Neck Cancers. Head and Neck, 26, 733-740.</mixed-citation></ref><ref id="scirp.81540-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Khan, Z., Khan, N., Tiwari, R.P., Patro, I.K., Prasad, G.B. and Bisen, P.S. (2010) Down-Regulation of Survivin by Oxaliplatin Diminishes Radioresistance of Head and Neck Squamous Carcinoma Cells. Radiotherapy and Oncology, 96, 267-273.  
https://doi.org/10.1016/j.radonc.2010.06.005</mixed-citation></ref></ref-list></back></article>